January 19, 2019
Add to Twitter
English | عربي
Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target From Research Collaboration with Dicerna
• Collaboration seeks to develop novel treatments for chronic liver diseases, including nonalcoholic steatohepatitis (NASH)